IL112602A0 - N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy - Google Patents

N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy

Info

Publication number
IL112602A0
IL112602A0 IL11260295A IL11260295A IL112602A0 IL 112602 A0 IL112602 A0 IL 112602A0 IL 11260295 A IL11260295 A IL 11260295A IL 11260295 A IL11260295 A IL 11260295A IL 112602 A0 IL112602 A0 IL 112602A0
Authority
IL
Israel
Prior art keywords
methylbutylamine
epilepsy
chlorophenyl
dimethyl
treatment
Prior art date
Application number
IL11260295A
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of IL112602A0 publication Critical patent/IL112602A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11260295A 1994-02-11 1995-02-09 N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy IL112602A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402641A GB9402641D0 (en) 1994-02-11 1994-02-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
IL112602A0 true IL112602A0 (en) 1995-12-08

Family

ID=10750231

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11260295A IL112602A0 (en) 1994-02-11 1995-02-09 N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy

Country Status (5)

Country Link
AU (1) AU1578295A (en)
GB (1) GB9402641D0 (en)
IL (1) IL112602A0 (en)
WO (1) WO1995021615A1 (en)
ZA (1) ZA951088B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
AU2007200334B8 (en) * 1998-08-24 2010-10-21 Sepracor, Inc. Methods of using and compositions comprising dopamine reuptake inhibitors
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6288125B1 (en) * 2000-03-17 2001-09-11 Knoll Pharmaceuticals Company Treatment of hiatial hernia
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
KR20060080817A (en) * 2005-01-06 2006-07-11 씨제이 주식회사 A dicarboxylic acid salt of sibutramine
KR20060080818A (en) * 2005-01-06 2006-07-11 씨제이 주식회사 A sulphonic acid salt of sibutramine
US7432398B2 (en) 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
CN102786444A (en) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 Preparation method for sulfonates of sibutramine analogues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526656A (en) * 1967-05-25 1970-09-01 Parke Davis & Co (1-arylcyclobutyl)carbonyl carbamic acid derivatives
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
WO1994000114A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine

Also Published As

Publication number Publication date
WO1995021615A1 (en) 1995-08-17
GB9402641D0 (en) 1994-04-06
AU1578295A (en) 1995-08-29
ZA951088B (en) 1996-01-23

Similar Documents

Publication Publication Date Title
GB9411080D0 (en) Treatment
ZA939161B (en) Wastewater treatment.
HU9400288D0 (en) Regenerating pump and pumpshell thereof
IL112602A0 (en) N,n-dimethyl-1-Ú1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine in the treatment of epilepsy
EP0612513A3 (en) External skin treatment composition.
IL109437A0 (en) 2-Amino-4-quinolyldihydropyridines, processes for their preparation and their use
GB9410512D0 (en) Novel treatment
GB9308802D0 (en) Treatment
GB9411635D0 (en) Novel treatment
GB9408084D0 (en) Medical treatment
GB9309542D0 (en) Herbicidal treatment
ZA971217B (en) Diamond treatment.
ZA9610761B (en) Medical treatment.
GB9424852D0 (en) Fungicidal treatment
GB9316319D0 (en) Strand treatment
EP0679431A3 (en) Reactor and use thereof.
ZA948336B (en) Treatment
GB9310836D0 (en) Treatment
GB2279548B (en) Crop treatment
GB9415606D0 (en) Strand treatment
GB9321793D0 (en) Medical treatment
GB9310611D0 (en) Skin treatment
GB2286824B (en) Wastewater treatment
GB9410971D0 (en) Diabetes treatment
GB9311268D0 (en) Crop treatment